General Counsel and Secretary Scimeca Dario converted options into 25,312 shares and sold $42,765 worth of shares (8,928 units at $4.79), increasing direct ownership by 206% to 24,353 units (SEC Form 4)

$DTIL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $DTIL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scimeca Dario

(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E PETTIGREW STREET, SUITE A-100

(Street)
DURHAM NC 27701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel and Secretary
3. Date of Earliest Transaction (Month/Day/Year)
01/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/20/2025 M 25,312(1) A (2) 33,281 D
Common Stock 01/22/2025 S(3) 8,928 D $4.79 24,353 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 01/20/2025 M 1,977 (4) (4) Common Stock 1,977 $0 1,978 D
Restricted Stock Units (2) 01/20/2025 M 8,427 (5) (5) Common Stock 8,427 $0 16,850 D
Restricted Stock Units (2) 01/20/2025 M 14,908 (6) (6) Common Stock 14,908 $0 29,815 D
Explanation of Responses:
1. Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. The sales were effected pursuant to a Rule 10b5-1 plan adopted on July 14, 2023. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
4. On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
5. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
6. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
/s/ Dario Scimeca 01/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $DTIL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DTIL

DatePrice TargetRatingAnalyst
1/10/2025$34.00Market Perform → Outperform
BMO Capital Markets
4/30/2024$19.00Buy
Guggenheim
6/17/2022$7.00Outperform
BMO Capital Markets
6/9/2022Outperform → Mkt Perform
William Blair
9/10/2021$23.00 → $26.00Buy
Stifel
More analyst ratings

$DTIL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025. Presentation Details: Date: Monday, April 7, 2025 Time: 3:00 PM ET in Track 2 Format: Presentation Webcast Registration: Link A live webcast will also be accessible on Precision's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

    - Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 - - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 - - Announced complete clinical response in first infant dosed by partner iECURE in ongoing Phase 1/2 clinical

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting

    First participant dosed achieved complete clinical response per study protocol and data suggests partial restoration of functional OTC enzyme activity in the liver iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that data presented at the 2025 ACMG Annual Clinical Genetics Meeting from the ongoing OTC-HOPE Phase 1/2 study of ECUR-506 suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed. "Long-term restoration of ornithine transcarbamylase activity has the potential to allow i

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$DTIL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DTIL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$DTIL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DTIL
SEC Filings

See more

$DTIL
Leadership Updates

Live Leadership Updates

See more
  • Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

    - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

    Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Precision BioSciences Appoints Melinda Brown to Board of Directors

    New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$DTIL
Financials

Live finance-specific insights

See more
  • Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Precision BioSciences to Report Third Quarter Results on November 4, 2024

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enab

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Precision BioSciences to Report Second Quarter Results on August 1, 2024

    Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more inten

    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$DTIL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more